{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:33:30Z","timestamp":1789187610014,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09958-x","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:02:07Z","timestamp":1728388927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4124-6085","authenticated-orcid":false,"given":"Mohammadreza","family":"Heydari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-0972","authenticated-orcid":false,"given":"Zohre","family":"Foroozanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2128-0924","authenticated-orcid":false,"given":"Sina","family":"Bazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8075-0427","authenticated-orcid":false,"given":"Zahra","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8498-5331","authenticated-orcid":false,"given":"Hassan","family":"Joulaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-1041","authenticated-orcid":false,"given":"Ghavam","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"9958_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2217\/pgs-2017-0194","volume":"18","author":"MA Bahar","year":"2017","unstructured":"Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug\u2013drug interaction and drug\u2013drug\u2013gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017;18:701\u201339.","journal-title":"Pharmacogenomics"},{"key":"9958_CR2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1177\/1060028013504075","volume":"47","author":"A Tseng","year":"2013","unstructured":"Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013;47:1429\u201339.","journal-title":"Ann Pharmacother"},{"key":"9958_CR3","doi-asserted-by":"publisher","unstructured":"Peng Y, Cheng Z, Xie F. Evaluation of pharmacokinetic drug-drug interactions: a review of the mechanisms, in Vitro and in Silico approaches. Metabolites. 2021;11. https:\/\/doi.org\/10.3390\/metabo11020075.","DOI":"10.3390\/metabo11020075"},{"key":"9958_CR4","doi-asserted-by":"publisher","first-page":"e25449","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23:e25449.","journal-title":"J Int AIDS Soc"},{"key":"9958_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","volume":"42","author":"D Cattaneo","year":"2020","unstructured":"Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJ, Gervasoni C. Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review. Ther Drug Monit. 2020;42:64\u201374.","journal-title":"Ther Drug Monit"},{"key":"9958_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/17512433.2018.1549484","volume":"11","author":"G Guaraldi","year":"2018","unstructured":"Guaraldi G, Pintassilgo I, Milic J, Mussini C. Managing antiretroviral therapy in the elderly HIV patient. Expert Rev Clin Pharmacol. 2018;11:1171\u201381.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9958_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/pds.5415","volume":"31","author":"C Leal Rodr\u00edguez","year":"2022","unstructured":"Leal Rodr\u00edguez C, et al. Drug interactions in hospital prescriptions in Denmark: prevalence and associations with adverse outcomes. Pharmacoepidemiol Drug Saf. 2022;31:632\u201342. https:\/\/doi.org\/10.1002\/pds.5415.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9958_CR8","doi-asserted-by":"crossref","unstructured":"Marin S et al. The management of polypharmacy in people living with HIV. AIDS Rev 25 (2023).","DOI":"10.24875\/AIDSRev.M23000059"},{"key":"9958_CR9","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1097\/QAD.0000000000001401","volume":"31","author":"JM Smith","year":"2017","unstructured":"Smith JM, Flexner C. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. Aids. 2017;31:S173\u201384.","journal-title":"Aids"},{"key":"9958_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/hiv.13206","volume":"23","author":"T Naito","year":"2022","unstructured":"Naito T, et al. Comorbidities and co-medications among 28 089 people living with HIV: a nationwide cohort study from 2009 to 2019 in Japan. HIV Med. 2022;23:485\u201393.","journal-title":"HIV Med"},{"key":"9958_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/apc.2022.0040","volume":"36","author":"B Olivieri-Mui","year":"2022","unstructured":"Olivieri-Mui B, et al. Geriatric conditions associated with nonadherence to antiretroviral therapy among older people with HIV: the importance of frailty. AIDS Patient Care STDs. 2022;36:226\u201335.","journal-title":"AIDS Patient Care STDs"},{"key":"9958_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/COH.0000000000000608","volume":"15","author":"EJ Edelman","year":"2020","unstructured":"Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15:126.","journal-title":"Curr Opin HIV AIDS"},{"key":"9958_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jiac.2020.04.003","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen R, et al. Use of comedications and potential drug-drug interactions in people living with HIV in China. J Infect Chemother. 2020;26:722\u20138.","journal-title":"J Infect Chemother"},{"key":"9958_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/JNC.0000000000000028","volume":"30","author":"JL Harmon","year":"2019","unstructured":"Harmon JL, McGee KS. Addressing polypharmacy in older adults living with HIV. J Assoc Nurses AIDS Care. 2019;30:73\u20139.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"9958_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/jrms.JRMS_689_18","volume":"24","author":"M Farrokhi","year":"2019","unstructured":"Farrokhi M, Gholami M, Mohraz M, McFarland W, Baesi K, Abbasian L. HIV drug resistance among na\u00efve HIV-infected patients in Iran. J Res Med Sci. 2019;24:31. https:\/\/doi.org\/10.4103\/jrms.JRMS_689_18.","journal-title":"J Res Med Sci"},{"key":"9958_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","volume":"12","author":"C Marzolini","year":"2019","unstructured":"Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol. 2019;12:643\u201359.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9958_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cid\/ciz811","volume":"71","author":"B L\u00f3pez-Centeno","year":"2020","unstructured":"L\u00f3pez-Centeno B, et al. Polypharmacy and drug\u2013drug interactions in people living with human immunodeficiency virus in the region of Madrid, Spain: a population-based study. Clin Infect Dis. 2020;71:353\u201362.","journal-title":"Clin Infect Dis"},{"key":"9958_CR18","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s11606-013-2449-6","volume":"28","author":"C Holtzman","year":"2013","unstructured":"Holtzman C, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28:1302\u201310.","journal-title":"J Gen Intern Med"},{"key":"9958_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-018-0817-0","volume":"18","author":"M Ssonko","year":"2018","unstructured":"Ssonko M, et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatr. 2018;18:1\u20138.","journal-title":"BMC Geriatr"},{"key":"9958_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/apc.2018.0190","volume":"33","author":"AM Kong","year":"2019","unstructured":"Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis. AIDS Patient Care STDs. 2019;33:93\u2013103.","journal-title":"AIDS Patient Care STDs"},{"key":"9958_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/qad.0000000000003514","volume":"37","author":"CD Johnston","year":"2023","unstructured":"Johnston CD, O\u2019Brien R, C\u00f4t\u00e9 HCF. Inclusion of women in HIV research and clinical trials. Aids. 2023;37:995\u20137. https:\/\/doi.org\/10.1097\/qad.0000000000003514.","journal-title":"Aids"},{"key":"9958_CR22","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3889\/oamjms.2019.744","volume":"7","author":"T Assadi","year":"2019","unstructured":"Assadi T, Sadeghi F, Noyani A, SeidAbadi AM, Yekesadat SM. Occupational burnout and its related factors among Iranian nurses: a cross-sectional study in Shahroud, Northeast of Iran. Open Access Macedonian J Med Sci. 2019;7:2902.","journal-title":"Open Access Macedonian J Med Sci"},{"key":"9958_CR23","first-page":"0","volume":"19","author":"M Sartipi","year":"2016","unstructured":"Sartipi M, Nedjat S, Mansournia MA, Baigi V, Fotouhi A. Assets as a socioeconomic status index: categorical principal components analysis vs. latent class analysis. Arch Iran Med. 2016;19:0\u20130.","journal-title":"Arch Iran Med"},{"key":"9958_CR24","unstructured":"Drug Interactions. Understanding the Risk, www.fda.gov\/drugs\/special-features\/drug-interactions-understanding-risk. Accessed Augest 27, 2016.> ("},{"key":"9958_CR25","doi-asserted-by":"publisher","unstructured":"Pinkoh R, Rodsiri R, Wainipitapong S. Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com\u00ae, Lexicomp\u00ae, and Epocrates\u00ae. PLoS ONE. 2023;18:e0287575. https:\/\/doi.org\/10.1371\/journal.pone.0287575.","DOI":"10.1371\/journal.pone.0287575"},{"key":"9958_CR26","doi-asserted-by":"publisher","unstructured":"Drugs.com. Drug Information Online 2004. Reference Reviews 18, 41\u201341 (2004). https:\/\/doi.org\/10.1108\/09504120410552697","DOI":"10.1108\/09504120410552697"},{"key":"9958_CR27","first-page":"24","volume":"16","author":"M Shafiekhani","year":"2017","unstructured":"Shafiekhani M, Karimi S, ali Davarpanah M, Vazin A. Evaluating drug interactions, adverse drug reactions, and level of adherence to highly active antiretroviral therapy regimen amongst HIV-positive patients who referred to an AIDS healthcare center in Fars, southern Iran: the first multifaceted study from Iran. HIV AIDS Rev Int J HIV-Related Probl. 2017;16:24\u201331.","journal-title":"HIV AIDS Rev Int J HIV-Related Probl"},{"key":"9958_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jgs.12695","volume":"62","author":"M Greene","year":"2014","unstructured":"Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug\u2013drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62:447\u201353.","journal-title":"J Am Geriatr Soc"},{"key":"9958_CR29","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/jac\/dkr248","volume":"66","author":"C Marzolini","year":"2011","unstructured":"Marzolini C, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107\u201311. https:\/\/doi.org\/10.1093\/jac\/dkr248.","journal-title":"J Antimicrob Chemother"},{"key":"9958_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/qad.0000000000001756","volume":"32","author":"AC Justice","year":"2018","unstructured":"Justice AC, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. Aids. 2018;32:739\u201349. https:\/\/doi.org\/10.1097\/qad.0000000000001756.","journal-title":"Aids"},{"key":"9958_CR31","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/phar.2043","volume":"37","author":"IR McNicholl","year":"2017","unstructured":"McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi EA. Pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-Positive patients. Pharmacotherapy. 2017;37:1498\u2013506. https:\/\/doi.org\/10.1002\/phar.2043.","journal-title":"Pharmacotherapy"},{"key":"9958_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1086\/652149","volume":"50","author":"JG Evans-Jones","year":"2010","unstructured":"Evans-Jones JG, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2010;50:1419\u201321. https:\/\/doi.org\/10.1086\/652149.","journal-title":"Clin Infect Dis"},{"key":"9958_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3851\/imp1540","volume":"15","author":"C Marzolini","year":"2010","unstructured":"Marzolini C, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15:413\u201323. https:\/\/doi.org\/10.3851\/imp1540.","journal-title":"Antivir Ther"},{"key":"9958_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/qai.0000000000001653","volume":"78","author":"A Ranzani","year":"2018","unstructured":"Ranzani A, et al. Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a Population of HIV-Positive patients aged 50 years or older. J Acquir Immune Defic Syndr. 2018;78:193\u2013201. https:\/\/doi.org\/10.1097\/qai.0000000000001653.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9958_CR35","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1592\/phco.27.10.1379","volume":"27","author":"CD Miller","year":"2007","unstructured":"Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy. 2007;27:1379\u201386. https:\/\/doi.org\/10.1592\/phco.27.10.1379.","journal-title":"Pharmacotherapy"},{"key":"9958_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1345\/aph.1P576","volume":"45","author":"N Patel","year":"2011","unstructured":"Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011;45:317\u201324. https:\/\/doi.org\/10.1345\/aph.1P576.","journal-title":"Ann Pharmacother"},{"key":"9958_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1592\/phco.31.5.480","volume":"31","author":"P Yiu","year":"2011","unstructured":"Yiu P, Nguyen NN, Holodniy M. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy. 2011;31:480\u20139. https:\/\/doi.org\/10.1592\/phco.31.5.480.","journal-title":"Pharmacotherapy"},{"key":"9958_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18332\/popmed\/149454","volume":"4","author":"S Park","year":"2022","unstructured":"Park S, et al. Drug-drug interactions with antiretroviral therapy among people living with HIV in Asia and other regions: risk factors and impact on indicators of health-related quality of life. Popul Med. 2022;4:1\u201315.","journal-title":"Popul Med"},{"key":"9958_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","volume":"30","author":"HB Krentz","year":"2016","unstructured":"Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016;30:11\u20137. https:\/\/doi.org\/10.1089\/apc.2015.0199.","journal-title":"AIDS Patient Care STDS"},{"key":"9958_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","volume":"12","author":"C Marzolini","year":"2019","unstructured":"Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol. 2019;12:643\u201359. https:\/\/doi.org\/10.1080\/17512433.2019.1627200.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9958_CR41","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815\u201331. https:\/\/doi.org\/10.1007\/s40262-013-0075-4.","journal-title":"Clin Pharmacokinet"},{"key":"9958_CR42","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/qai.0000000000000983","volume":"72","author":"IH Song","year":"2016","unstructured":"Song IH, et al. The Effect of Dolutegravir on the pharmacokinetics of Metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72:400\u20137. https:\/\/doi.org\/10.1097\/qai.0000000000000983.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9958_CR43","unstructured":"Zhang H et al. in 18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June. 14\u201316."},{"key":"9958_CR44","doi-asserted-by":"publisher","unstructured":"Kumar P, et al. Differential Influence of the antiretroviral pharmacokinetic enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic\/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017;61. https:\/\/doi.org\/10.1128\/aac.01201-17.","DOI":"10.1128\/aac.01201-17"},{"key":"9958_CR45","first-page":"245","volume":"19","author":"G Psevdos Jr","year":"2009","unstructured":"Psevdos G Jr., Gonzalez E, Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged Vancomycin course for osteomyelitis. AIDS Read. 2009;19:245\u20138.","journal-title":"AIDS Read"},{"key":"9958_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/s1807-59322011000100003","volume":"66","author":"AM Reis","year":"2011","unstructured":"Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clin (Sao Paulo). 2011;66:9\u201315. https:\/\/doi.org\/10.1590\/s1807-59322011000100003.","journal-title":"Clin (Sao Paulo)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09958-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09958-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09958-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:01:55Z","timestamp":1728432115000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09958-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9958"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09958-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Shiraz University of medical Sciences ethical committee under ethical code: IR.SUMS.REC.1400.379. Considering that this study was conducted on human patients, after the approval of the Ethics Committee of Shiraz University of Medical Sciences, an informed written consent form was completed by all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1123"}}